Abstract
Background
The goal of this study was to investigate whether ceftriaxone combination therapy
is associated with better clinical outcomes than respiratory fluoroquinolone monotherapy
for adults with community-acquired pneumonia (CAP). We conducted a meta-analysis of
published studies.
Methods
Using the PubMed, EMBASE, and Cochrane Library databases, we performed a literature
search of available randomized controlled trials (RCTs) published as original articles
before September 2017.
Results
Nine RCTs, involving 1520 patients, were included in the meta-analysis. The pooled
relative risks (RRs) for the efficacy of ceftriaxone combination therapy versus respiratory
fluoroquinolones monotherapy were 0.96 (95% CI: 0.92–1.01), based on clinically evaluable
populations, and 0.93 (95% CI: 0.88–0.99) based on intention-to-treat (ITT) populations.
No statistically significant differences were observed in microbiological treatment
success (pooled RR = 0.99, 95% CI: 0.90–1.09), although drug-related adverse events were significantly
lower with ceftriaxone combination therapy than with respiratory fluoroquinolones
monotherapy (pooled RR = 1.27, 95% CI: 1.04–1.55).
Conclusions
Current evidence showed that the efficacy of ceftriaxone combination therapy was similar
to respiratory fluoroquinolone monotherapy for hospitalized CAP patients, and was
associated with lower drug-related adverse events.
Keywords
To read this article in full you will need to make a payment
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D; use, select 'Corporate R&D; Professionals'
Subscribe:
Subscribe to The American Journal of Emergency MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Incidence and cost of pneumonia in medicare beneficiaries.Chest. 2012; 142: 973-981
- Clinical and economic burden of community-acquired pneumonia among adults in Europe.Thorax. 2012; 67: 71-79
- Community-acquired pneumonia.Lancet. 2015; 386: 1097-1108
- Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia.Intensive Care Med. 2002; 28: 1030-1035
- Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database.Crit. Care. 2006; 10 (S1)
- Microbial pathogens of adult community-acquired pneumonia in Southern Estonia.Medicina (Kaunas). 2006; 42: 384-394
- The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy.Clin. Infect. Dis. 2008; 46: 1513-1521
- Microbial aetiology of community-acquired pneumonia and its relation to severity.Thorax. 2011; 66: 340-346
- Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus Pneumoniae in the United States.Nat. Med. 2003; 9: 424-430
- Changing trends in antimicrobial resistance and serotypes of Streptococcus Pneumoniae isolates in Asian countries: an Asian network for surveillance of resistant pathogens (ANSORP) study.Antimicrob. Agents Chemother. 2012; 56: 1418-1426
- Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.Clin. Infect. Dis. 2007; 44: S27-72
- Ceftriaxone and cefotaxime use in Victorian hospitals.Med. J. Aust. 2002; 176: 524-529
- Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors.Chest. 2005; 128: 172-183
- Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials.Int. J. Antimicrob. Agents. 2010; 36: 58-65
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.BMJ. 2011; 343d5928
- Quantifying heterogeneity in a meta-analysis.Stat. Med. 2002; 21: 1539-1558
- Meta-analysis in clinical trials.Control. Clin. Trials. 1986; 7: 177-188
- Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia.Eur. J. Clin. Microbiol. Infect. Dis. 2004; 23: 82-88
- A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia.Clin. Ther. 2002; 24: 1292-1308
- Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy.J Emerg Med. 2004; 27: 395-405
- High-dose levofloxacin in community-acquired pneumonia: a randomized, open-label study.Clin Drug Investig. 2012; 32: 569-576
- Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy.Clin. Infect. Dis. 2005; 41: 1697-1705
- Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia.Treat Respir Med. 2004; 3: 329-336
- Clinical efficacy of moxifloxacin in the treatment of Mycoplasma pneumonia.Chin. J. Infect. Chemother. 2010; 10: 349-353
- Efficacy and cost-effectiveness analysis of moxifloxacin hydrochloride and combination of ceftriaxone sodium with azithromycin in the treatment of moderate to severe community acquired pneumonia in elderly patients.Chin. J. New Drugs. 2009; 18
- Multicenter, open-label, randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin-clavulanate in the treatment of serious community-acquired pneumonia in adults.Clin. Infect. Dis. 2004; 38: S16-S23
- Eficacia del levofloxacino en el tratamiento de neumonía adquirida en la comunidad.Medicina Interna de México. 2013; 29: 588
- Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials.CMAJ. 2008; 179: 1269-1277
- Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization.Int. J. Antimicrob. Agents. 2005; 25: 75-83
- Respiratory fluoroquinolones monotherapy versus β-lactams plus macrolides combination therapy for non-ICU hospitalized community-acquired pneumonia patients: a meta-analysis.Chinese Journal of Evidence-Based Medicine. 2015; 15: 824-832
- Azithromycin for acute lower respiratory tract infections.Cochrane Database Syst. Rev. 2015 Mar 8; CD001954
- FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects.(Available from:)
Article Info
Publication History
Published online: February 02, 2018
Accepted:
January 25,
2018
Received in revised form:
January 22,
2018
Received:
November 27,
2017
Identification
Copyright
© 2018 Elsevier Inc. All rights reserved.
